• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

FACSIMILE TRANSMISSION RECORD, September 9, 2010 - Corifact

FACSIMILE TRANSMISSION RECORD
Division of Blood Applications
1401 Rockville Pike, Suite 400N, HFM-380
Rockville, Maryland 20852-1448

FAX  (301) 827-2857
TEL  (301) 827-3524

 

FAX No.   610-878-4182
To:  David Desris, PharmD, CSL Behring, LLC
From:  Nannette Cagungun, OBRR/CBER/FDA
Date:  September 9, 2010

Re:  STN 125385/0

In order to facilitate the review of your submission, we have the following request for information regarding your Factor XIII BLA:

Study # BI 71023/0-1003 (Healthy subjects' PK)

  1. Please provide FXIII concentration-time data plot on a semi-log scale for each subject
    separately (only baseline corrected FXIII activity (U/mL).  In other words, 20 plots for 20
    subjects.   Please also provide a mean plot.

    Please ensure that in future submissions you do not use non-standardized PK terms.  For example, area under the curve from time zero to t (AUC(0-t)) or area under the curve from time zero to infinity (AUC(0-∞)) are standardized PK terms whereas AUDC or AUD are not.  

        Mean residence time (MRT) is standardized PK term whereas MRTvss is not.   

 Study # BI 71023_2002 (Patients' PK)

  1. Please provide the following information in a single table: age, weight, gender, and dose given to individual subjects.
  2. Please provide individual subject’s FXIII concentration-time data (activity and antigen) along with individual subject’s PK parameters.  If you have already submitted these data then please point out the location of these data.

We request that you submit the information as an amendment to the BLA as soon as possible.

Sincerely yours,

Nannette Cagungun
Regulatory Project Manager
DBA/OBRR/CBER/FDA
Tel: (301) 827-6174